<DOC>
	<DOCNO>NCT02477878</DOCNO>
	<brief_summary>A Phase I study BPX-501 T cell infusion adult recurrent minimal residual disease ( MRD ) hematologic malignancy post-allogeneic transplant . The treatment consist increase dos BPX-501 T cell infusion achieve clinical response . AP1903 investigate treatment aGvHD BPX-501 T cell infusion determine dose mitigate GvHD preserve graft-versus tumor effect .</brief_summary>
	<brief_title>Study Gene Modified Donor T Cell Infusion Patients With Recurrent Disease After Allogeneic Transplant</brief_title>
	<detailed_description>Un-manipulated donor lymphocyte infusion ( DLI ) use stem cell transplantation treat prevent relapse , prevent infection establish full donor chimerism . The addition mature T cell exhibit broad repertoire T cell immunity viral antigen , well cancer antigen , might provide clinical benefit . However , expect side effect presence mature T cell potential occurrence acute graft-versus-host disease ( aGvHD ) . The use suicide gene switch would trigger initiation apoptosis alloreactive T cell infusion drug would represent potential optimal strategy restore early immunity build `` safety switch '' GvHD side effect . Evidence emerge low-dose DLI follow dose escalation achieve high clinical response rate lower GvHD occurrence . Optimization DLI dose schedule well strategy donor T-cell manipulation may lead consistent ability separate GvHD GvT ( graft-versus-tumor ) activity improve safety DLI treatment . Our strategy infuse escalate dos manipulate T cell ( donor provide original hematopoietic stem cell graft ) adult recurrent minimal residual disease ( MRD ) hematologic malignancy post-allogeneic transplant accelerate immune reconstitution thus improve graft versus leukemic effect reduce severity GvHD .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>1 . Clinical diagnosis one following : 1. leukemia 2. myelodysplasia 3. lymphoma 4. multiple myeloma 5 . Other highrisk hematologic malignancy eligible stem cell transplantation per institutional standard 2 . Recurrent disease present &gt; 100 day , minimal residual disease ( MRD ) present &gt; 30 day either : 1 . Matched related HSCT 2 . Mismatched related HSCT 3 . Life expectancy &gt; 10 week ; 4 . Signed donor patient/guardian inform consent ; 5 . A minimum genotypic identical match 4/8 require , determine high resolution typing , least one allele follow genetic locus : HLAA , HLAB , HLACw , HLA DRB1 . 6 . Performance status : Karnofsky/Lansky score &gt; 50 % . 7 . Subjects adequate organ function measure : 1 . Bone marrow : &gt; 25 % donor Tcell chimerism peripheral blood , obtain 3 week posttransplant ; ANC &gt; 1 x 10E9/L 2 . Cardiac : leave ventricular ejection fraction rest must ≥ 45 % 3 . Pulmonary : FEV 1 , FVC , DLCO ( diffusion capacity ) ≥ 50 % predict ( correct hemoglobin ) 4 . Hepatic : direct bilirubin ≤ 3 x upper limit normal , AST/ALT ≤ 5 x upper limit normal 5 . Renal : creatinine ≤ 2x ULN age 1 . ≥ Grade II acute GvHD chronic extensive GvHD due previous allograft time screen 2 . Active CNS involvement malignant cell ( ≤ 2 month condition ) 3 . Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) ; principal investigator final arbiter criterion 4 . Positive HIV serology viral RNA 5 . Pregnancy ( positive serum urine βHCG test ) breastfeed 6 . Fertile men woman unwilling use effective form birth control abstinence one year transplantation 7 . Bovine product allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adult leukemias myelodysplasia</keyword>
	<keyword>Adult lymphoma</keyword>
	<keyword>Adult multiple myeloma</keyword>
</DOC>